Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Japan approves Sumitomo Pharma's Amchepry and Cuorips' ReHeart as world's first induced pluripotent stem cell therapies
Cell therapy, neurological, cardiovascular, iPS cells, Parkinson's disease, heart failure - Read more

AstraZeneca's Calquence (acalabrutinib) plus AbbVie's Venclexta (venetoclax) wins FDA approval for first-line chronic lymphocytic leukemia
Small molecule, cancer, BTK inhibitor, chronic lymphocytic leukemia, BCL-2 inhibitor, combination therapy - Read more

MHRA approves zanidatamab (Ziihera) targeting HER2 protein for advanced biliary tract cancer treatment
Antibody, cancer, monoclonal antibody, biliary tract cancer, HER2 target - Read more

Vanda Pharmaceuticals wins FDA approval for Bysanti (milsaperidone) targeting bipolar I disorder and schizophrenia
Small molecule, neurological, antipsychotic, bipolar disorder, schizophrenia, dopamine D2 antagonist - Read more

CStone Pharmaceuticals' sugemalimab wins UK MHRA approval for stage III non-small cell lung cancer
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, PD-L1 inhibitor - Read more

Novartis divests 71% stake in Novartis India Limited to ChrysCapital consortium for $159M
Divestiture, generics, established brands, strategic transformation - Read more

LEON, Harro Höfliger announce strategic collaboration for global distribution of nanoencapsulation equipment
Strategic collaboration, nanoencapsulation, manufacturing, drug delivery, commercialization - Read more

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

Virion Therapeutics reports sustained anti-hepatitis B virus immunity from single VRON-0200 dose in Ph1 study
Immunotherapy, infectious disease, T cell therapy, hepatitis B, checkpoint modifier, combination therapy - Read more

MoonLake Immunotherapeutics reports positive Ph2 results for sonelokimab targeting IL-17A/F in axial spondyloarthritis
Antibody, autoimmune, nanobody, axial spondyloarthritis, IL-17 inhibitor - Read more

Johnson & Johnson's TREMFYA (guselkumab) shows sustained remission through 3 years in ulcerative colitis extension study
Monoclonal antibody, autoimmune, ulcerative colitis, IL-23 inhibitor, long-term efficacy - Read more

Candel Therapeutics lands $100M royalty deal to fund prostate cancer drug launch
Oncology, oncolytic virus, prostate cancer, clinical-stage - Read more

Herantis Pharma receives €8M ($9.4M) Horizon grant for Parkinson's disease HER-096 Phase 2 trial
Neurological, Parkinson's disease, clinical-stage, disease-modifying therapies - Read more

Supreme Court strikes down Trump's emergency tariffs 6-3, ruling president overstepped authority under IEEPA
Regulatory, strategic, financial, operational - Read more

Roche receives FDA decision date for giredestrant (giredestrant) targeting advanced breast cancer following Ph3 success
Small molecule, cancer, SERD, breast cancer, hormone therapy - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Ionis Pharmaceuticals terminates ION269 Ph1 trial for Alzheimer's disease in Down syndrome patients due to slow enrollment
Antisense oligonucleotide, neurological, Alzheimer disease, Down syndrome, amyloid plaques - Read more

Grail's Galleri multi-cancer early detection test fails primary endpoint in NHS trial of 142,000 participants
Diagnostic test, cancer, multi-cancer early detection, liquid biopsy, screening - Read more

Catalent cuts 96 more jobs in Maryland following reduced demand from large commercial customer
Gene therapy, rare disease, operational, cost reduction - Read more

FDA's Tracy Beth Høeg announces safety probes into antidepressants and RSV antibodies during pregnancy
Monoclonal antibody, neurological, operational, safety - Read more

Roche seeks to divest Rocephin antibiotic and Basel production facility amid generic competition
Divestment, infectious disease, manufacturing, antibiotic - Read more

Biohaven cuts R&D 60% after FDA rejection, pivots strategy to focus on obesity opportunities
Small molecule, neurological, strategic, cost reduction, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here